JH Kao

Kao, J. ., Yu, M. ., Chen, C. ., Peng, C. ., Chen, M. ., Tang, H. ., … Wu, J. . (2018). Twelve-week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.14096 (Original work published 2018)

Wang, C. ., Tseng, T. ., & Kao, J. . (2015). Hepatitis B virus infection and metabolic syndrome: fact or fiction?. Journal of Gastroenterology and Hepatology, 30(1), 14-20. https://doi.org/10.1111/jgh.12700

Hsu, C. ., & Kao, J. . (2013). Fluvastatin helps interferon-based therapy in chronic hepatitis C: fact or fiction?. Journal of Gastroenterology and Hepatology, 28(1), 7-9. https://doi.org/10.1111/jgh.12024

Liu, C. ., & Kao, J. . (2019). Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction?. Alimentary Pharmacology & Therapeutics, 49(2), 229-230. https://doi.org/10.1111/apt.15056

Hsu, S. ., Yang, S. ., & Kao, J. . (2020). Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?. Journal of the Formosan Medical Association = Taiwan Yi Zhi, 119(1 Pt 1), 3-11. https://doi.org/10.1016/j.jfma.2019.09.006